Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US launch for Xenazine

This article was originally published in Scrip

Executive Summary

Ovation Pharmaceuticalshas launched Xenazine (tetrabenazine) in the US, making it the first product for the treatment of chorea in Huntington's disease to be made available there. The product has a wholesale acquisition cost of about $3,000 for a 12mg bottle and $6,000 for 25mg, which gives an annual price of between $30,000 and $50,000 depending on the individual patient's needs, Ovation says. It will be marketed by Ovation's 48-person sales force to specialists in CNS disorders, and the company is offering a financial patient support programme for those in need.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007402

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel